Fagron and PureIMS have joined forces to make CYCLOPS® dry powder inhaler available nationwide in the Netherlands. The two Dutch pharmaceutical companies recently signed an agreement, granting Fagron the exclusive rights to organize the national distribution of PureIMS’s compounded preparations, such as an inhaled antibiotic for the treatment of pulmonary Pseudomonas aeruginosa infections caused by cystic fibrosis.
Cyclops® dry powder inhaler is characterized by its user-friendliness and hygienic design, and has been specially developed for high-dose inhalation powders, such as antibiotics. With Cyclops®, patients can discreetly inhale such medications at home or on the go within a minute. PureIMS currently produces one inhaled antibiotic in Cyclops® as a compounded preparation under GMP quality standards.
With the collaboration between PureIMS and Fagron, Cyclops® will now be distributed nationwide in the Netherlands through dispensing via Infinity Pharma. Infinity Pharma specializes in patient-specific drug compounding and is equipped to provide active patient support. This ensures that the innovative and user-friendly inhaler will be available to as many patients as possible and can always be delivered in a short time frame.
Fagron takes its first steps into the distribution of dry powder inhalation products with the collaboration. Sjoerd van Olffen, Product & Innovation Manager at Fagron, explains: “Inhalation is a very patient-friendly route of drug delivery. Because the patient is central to everything Fagron does, innovations like Cyclops® fit well within our product line, and we are very pleased with this addition.”
Jaap Wieling, CEO of PureIMS, is delighted with the partnership on their compounded preparation. “The collaboration is an important step forward for our company. We know that many patients can benefit from using Cyclops®-based inhaled medication. It is therefore fantastic that we can now serve patients across the Netherlands with excellent support, thanks to Fagron and Infinity Pharma. At the same time, we work towards marketing approval of our products within the EU, the United States, and beyond.”
About PureIMS B.V.
PureIMS, a Netherlands-based pharmaceutical company, owns exclusive worldwide license rights of Cyclops® dry powder inhaler The inhaler is a superior alternative to a wide range of oral and parenteral dosage forms for pulmonary, systemic and rescue indications.
In addition to partnering programs, PureIMS has a clinical stage in-house pipeline also open to outlicensing; lead programs are Cyclops® inhalers for levodopa (PD), epinephrine (anaphylaxis) and colistin (CF and NCFB).
For more information, please visit www.pureims.com
About Fagron
Fagron is a leading global pharmaceutical compounding company, dedicated to improving personalized medicine. By offering innovative solutions, such as high-quality raw materials, formulations, and specialized services, Fagron enables healthcare professionals to meet the specific needs of patients. With a strong focus on safety, quality, and innovation, Fagron operates in over 30 countries, serving hospitals, pharmacies, and other healthcare institutions worldwide. The company is committed to advancing patient care by offering tailored treatment options and delivering exceptional pharmaceutical expertise.
For more information, please visit www.fagron.com
For further inquiries, please contact:
Frank Lambert, Executive Director Commercialization
PureIMS bv
Ceintuurbaan Noord 152
9301NZ RODEN, The Netherlands
+316-51707297
flambert@pureims.com
